72004 Federal Register / Vol. 79, No. 233 / Thursday, December 4, 2014 / Notices 

related questions with inquiries into the 

communication channels through which 

understanding is being obtained, and 

assessment of FDA-regulated material. 

This survey will extend the information 

collected and priorities from HINTS 

which have been to provide a 

comprehensive assessment of the 

American public’s current access to, and 

use of, information about cancer across 

the cancer care continuum from cancer 

prevention, early detection, diagnosis, 

treatment, and survivorship. 

OMB approval is requested for 1 year. 

There are no costs to respondents other 

than their time. The total estimated 

annualized burden hours are 2,159. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total annual 

burden hour 

Individuals ........................................................................................................ 4,318 1 30/60 2,159 

Dated: November 24, 2014. 

Karla Bailey, 

NCI Project Clearance Liaison, National 

Institutes of Health. 

[FR Doc. 2014–28513 Filed 12–3–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Proposed Collection; 60-Day Comment 

Request; Surveys and Interviews To 

Support an Evaluation of the 

Innovative Molecular Analysis 

Technologies (IMAT) Program (NCI) 

SUMMARY: In compliance with the 

requirement of Section 3506(c)(2)(A) of 

the Paperwork Reduction Act of 1995, 

for opportunity for public comment on 

proposed data collection projects, the 

National Cancer Institute (NCI), 

National Institutes of Health (NIH), will 

publish periodic summaries of proposed 

projects to be submitted to the Office of 

Management and Budget (OMB) for 

review and approval. 

Written comments and/or suggestions 

from the public and affected agencies 

are invited on one or more of the 

following points: (1) Whether the 

proposed collection of information is 

necessary for the proper performance of 

the function of the agency, including 

whether the information will have 

practical utility; (2) The accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; (3) 

Ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (4) Ways to minimize the 

burden of the collection of information 

on those who are to respond, including 

the use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology. 

To Submit Comments and For Further 

Information: To obtain a copy of the 

data collection plans and instruments, 

submit comments in writing, or request 

more information on the proposed 

project, contact: Anthony Dickherber, 

NCI Center for Strategic Scientific 

Initiatives, 31 Center Drive, Rm10A33, 

Bethesda, MD 20892 or call non-toll-free 

number 301–547–9980 or Email your 

request, including your address to: 

dickherberaj@mail.nih.gov. Formal 

requests for additional plans and 

instruments must be requested in 

writing. 

Comment Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 60 days of the date of 

this publication. 

Proposed Collection: Surveys and 

Interviews to Support an Evaluation of 

the Innovative Molecular Analysis 

Technologies (IMAT) Program (NCI), 

0925–NEW, National Cancer Institute 

(NCI), National Institutes of Health 

(NIH). 

Need and Use of Information 

Collection: The purpose of the proposed 

evaluation is to pursue a comprehensive 

process and outcome assessment of the 

15-year old Innovative Molecular 

Analysis Technologies (IMAT) program. 

While the program consistently offers 

promising indicators of success, the full 

program has not been evaluated since 

2008, and never in as comprehensive a 

manner as has been formulated in the 

current evaluation plan. An outcome 

evaluation of the long-standing National 

Cancer Institute’s (NCI) IMAT program 

presents a rich and unique opportunity 

likely to serve institutes across the 

National Institutes of Health (NIH), and 

perhaps other federal agencies, 

considering the costs and benefits of 

directing resources towards supporting 

technology development. An award 

through the NIH Evaluation Set-Aside 

program to support this evaluation, for 

which NIH-wide relevance is a principle 

element of determining merit for 

support, is testament to this. The 

evaluation serves as an opportunity to 

gauge the impact of investments in 

technology development and also to 

assess the strengths and weaknesses of 

phased innovation award mechanisms. 

Like all institutes and centers (ICs) of 

the NIH, NCI seeks opportunities for 

improving their programs’ utility for the 

broad continuum of researchers, 

clinicians and ultimately patients. NCI 

Director Harold Varmus and other 

leadership across NCI, as well as the 

NCI Board of Scientific Advisors, will 

be the primary users of the evaluation 

results. Findings are primarily intended 

for considering the long-term strategy to 

support innovative technology 

development and how to more 

efficiently translate emerging 

capabilities through such technologies 

into the promised benefits for cancer 

research and clinical care. Interviews 

with grantees, program officers, review 

officers, and other NIH awardees make 

up a crucial component of the 

evaluation plan and will largely follow 

set survey protocols. Specific near-term 

aims include the use of this information 

to consider the utility of continued 

investment through existing 

solicitations and in strategic planning 

generally for institute support for 

innovative technology development. 

OMB approval is requested for 1 year. 

There are no costs to respondents other 

than their time. The total estimated 

annualized burden hours are 575. 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 79, No. 233 / Thursday, December 4, 2014 / Notices 72005 

ESTIMATED ANNUALIZED BURDEN HOURS

Form name Type of respondents Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total annual 

burden hours 

IMAT Awardee Interview ................... IMAT Awardees ............................... 100 1 1 100 

Evaluation Web-based Survey .......... IMAT Awardees, and other NIH 

Awardees (Comparison group).

900 1 30/60 450 

Tech End Users Interview ................. Technology End-Users .................... 50 1 30/60 25 

Dated: November 24, 2014. 

Karla Bailey, 

NCI Project Clearance Liaison, National 

Institutes of Health. 

[FR Doc. 2014–28498 Filed 12–3–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of HHS-Certified 

Laboratories and Instrumented Initial 

Testing Facilities Which Meet Minimum 

Standards To Engage in Urine Drug 

Testing for Federal Agencies 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) notifies federal 

agencies of the laboratories and 

Instrumented Initial Testing Facilities 

(IITF) currently certified to meet the 

standards of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs (Mandatory Guidelines). The 

Mandatory Guidelines were first 

published in the Federal Register on 

April 11, 1988 (53 FR 11970), and 

subsequently revised in the Federal 

Register on June 9, 1994 (59 FR 29908); 

September 30, 1997 (62 FR 51118); 

April 13, 2004 (69 FR 19644); November 

25, 2008 (73 FR 71858); December 10, 

2008 (73 FR 75122); and on April 30, 

2010 (75 FR 22809). 

A notice listing all currently HHScertified laboratories and IITFs is 

published in the Federal Register 

during the first week of each month. If 

any laboratory or IITF certification is 

suspended or revoked, the laboratory or 

IITF will be omitted from subsequent 

lists until such time as it is restored to 

full certification under the Mandatory 

Guidelines. 

If any laboratory or IITF has 

withdrawn from the HHS National 

Laboratory Certification Program (NLCP) 

during the past month, it will be listed 

at the end and will be omitted from the 

monthly listing thereafter. 

This notice is also available on the 

Internet at http://beta.samhsa.gov/

workplace. 

FOR FURTHER INFORMATION CONTACT: 

Giselle Hersh, Division of Workplace 

Programs, SAMHSA/CSAP, Room 7– 

1051, One Choke Cherry Road, 

Rockville, Maryland 20857; 240–276– 

2600 (voice), 240–276–2610 (fax). 

SUPPLEMENTARY INFORMATION: The 

Mandatory Guidelines were initially 

developed in accordance with Executive 

Order 12564 and section 503 of Public 

Law 100–71. The ‘‘Mandatory 

Guidelines for Federal Workplace Drug 

Testing Programs,’’ as amended in the 

revisions listed above, requires strict 

standards that laboratories and IITFs 

must meet in order to conduct drug and 

specimen validity tests on urine 

specimens for federal agencies. 

To become certified, an applicant 

laboratory or IITF must undergo three 

rounds of performance testing plus an 

on-site inspection. To maintain that 

certification, a laboratory or IITF must 

participate in a quarterly performance 

testing program plus undergo periodic, 

on-site inspections. 

Laboratories and IITFs in the 

applicant stage of certification are not to 

be considered as meeting the minimum 

requirements described in the HHS 

Mandatory Guidelines. A HHS-certified 

laboratory or IITF must have its letter of 

certification from HHS/SAMHSA 

(formerly: HHS/NIDA), which attests 

that it has met minimum standards. 

In accordance with the Mandatory 

Guidelines dated November 25, 2008 

(73 FR 71858), the following HHScertified laboratories and IITFs meet the 

minimum standards to conduct drug 

and specimen validity tests on urine 

specimens: 

HHS-Certified Instrumented Initial 

Testing Facilities 

Gamma-Dynacare Medical Laboratories, 

6628 50th Street NW., Edmonton, AB 

Canada T6B 2N7, 780–784–1190 

HHS-Certified Laboratories 

ACM Medical Laboratory, Inc., 160 

Elmgrove Park, Rochester, NY 14624, 

585–429–2264 

Aegis Analytical Laboratories, Inc., 345 

Hill Ave., Nashville, TN 37210, 615– 

255–2400, (Formerly: Aegis Sciences 

Corporation, Aegis Analytical 

Laboratories, Inc., Aegis Analytical 

Laboratories) 

Alere Toxicology Services, 1111 Newton 

St., Gretna, LA 70053, 504–361–8989/ 

800–433–3823, (Formerly: Kroll 

Laboratory Specialists, Inc., 

Laboratory Specialists, Inc.) 

Alere Toxicology Services, 450 

Southlake Blvd., Richmond, VA 

23236, 804–378–9130, (Formerly: 

Kroll Laboratory Specialists, Inc., 

Scientific Testing Laboratories, Inc.; 

Kroll Scientific Testing Laboratories, 

Inc.) 

Baptist Medical Center-Toxicology 

Laboratory, 11401 I–30, Little Rock, 

AR 72209–7056, 501–202–2783, 

(Formerly: Forensic Toxicology 

Laboratory Baptist Medical Center) 

Clinical Reference Lab, 8433 Quivira 

Road, Lenexa, KS 66215–2802, 800– 

445–6917 

DrugScan, Inc., 200 Precision Road, 

Suite 200, Horsham, PA 19044, 800– 

235–4890 

ElSohly Laboratories, Inc., 5 Industrial 

Park Drive, Oxford, MS 38655, 662– 

236–2609 

Fortes Laboratories, Inc., 25749 SW., 

Canyon Creek Road, Suite 600, 

Wilsonville, OR 97070, 503–486–1023 

Gamma-Dynacare Medical 

Laboratories *, A Division of the 

Gamma-Dynacare Laboratory 

Partnership, 245 Pall Mall Street, 

London, ONT, Canada N6A 1P4, 519– 

679–1630 

Laboratory Corporation of America 

Holdings, 7207 N. Gessner Road, 

Houston, TX 77040, 713–856–8288/

800–800–2387 

Laboratory Corporation of America 

Holdings, 69 First Ave., Raritan, NJ 

08869, 908–526–2400/800–437–4986, 

(Formerly: Roche Biomedical 

Laboratories, Inc.) 

Laboratory Corporation of America 

Holdings, 1904 Alexander Drive, 

mstockstill on DSK4VPTVN1PROD with NOTICES